We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Far Infrared Radiation for Sickle Cell Pain Management

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2009 by GAAD Medical Research Institute Inc..
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00599482
First Posted: January 23, 2008
Last Update Posted: January 5, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
GAAD Medical Research Institute Inc.
January 11, 2008
January 23, 2008
January 5, 2009
January 2008
September 2008   (Final data collection date for primary outcome measure)
Pain Management [ Time Frame: 40 minutes ]
Same as current
Complete list of historical versions of study NCT00599482 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Far Infrared Radiation for Sickle Cell Pain Management
Phase 1 Study to Examine the Use of Far Infrared Radiation for Pain Management During Sickle Cell Crisis
Most patients with sickle-cell disease have periodic intensely painful episodes. To manage this pain, we are proposing the drinking of at least 500 mL of water followed by far infrared radiation.

Painful sickle cell crises are treated with hydration and analgesics. Ischemia is an absolute or relative shortage of the blood supply to an organ. Relative shortage means the mismatch of blood supply (oxygen delivery) and blood request for adequate oxygenation of tissue.

It is hereby postulated that far infrared radiation of the body will promote blood and oxygen supply to the affected tissues. In addition, the analgesic properties of far infrared will alleviate pain due to the crisis.

Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Anemia, Sickle Cell
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far infrared radiation for 30 to 40 minutes during each session.
1
Far Infrared Radiation
Intervention: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
10
January 2009
September 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • People with sickle cell disease

Exclusion Criteria:

Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00599482
GAAD-SCC-CTP1
Yes
Not Provided
Not Provided
Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
Not Provided
Study Chair: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
Study Director: Kwasi Donyina, Ph.D. GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP